Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …

Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes
and well‐established molecular drivers. Allogeneic haematopoietic stem cell transplantation …

The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …

Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …

We enjoyed the recent authoritative review by Dr Tefferi on current management of patients
with myelofibrosis. 1 The article provides guidance for hematologists and oncologists in both …

Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for
patients with primary myelofibrosis (PMF), but information on its net advantage over …

Primary or post–essential thrombocythemia/polycythemia vera myelofibrosis is a
Philadelphia-negative myeloproliferative neoplasm with a median survival of approximately …

Improvements in the field of allo-HSCT, the ability to improve patient's performance status
prior to transplant with JAK1/2 inhibitors and a more accurate disease risk stratification …

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging
because of the increasing use of allogeneic stem cell transplantation and new …

Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …